Protocol
Advice to eat fatty fish after a heart attack or with angina
In DART, men told to eat fatty fish after a heart attack had 29% lower 2-year death.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
At a glance
Two British trials tested telling men with heart disease to eat oily fish twice a week. The first, after heart attacks, found fewer deaths. The second, in men with angina, found no fewer deaths and more heart deaths, mostly in men given fish oil pills. With one trial for and one against, the evidence is unsettled.
- What was measured
- Deaths over 2 years (DART) and 3 to 9 years (DART-2).
- How big
- Men advised to eat fatty fish had 29% fewer deaths at 2 years in the first trial.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 2571009.
- Who it applies to
- Men with prior heart attack or angina in the UK. Women were not tested.
- Safety
- DART-2 found higher cardiac death with fish or fish oil advice, mainly with capsules.
- Compared with
- No fish advice.
- Certainty
- Grade C, resting on: Two randomized trials of dietary advice, one positive and one negative.
- What would change this grade
- Could rise to B with: Randomized trial of fatty fish meals. Who: Adults with coronary heart disease, men and women. Measured: Death and cardiovascular events. Length: At least 3 years.
- Cost
- No price recorded yet.
- Sources
- 2 studies cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In DART, men told to eat fatty fish after a heart attack had 29% lower 2-year death. When the same group repeated the trial in 3,114 men with angina (DART-2), fish advice did not reduce death and cardiac death was higher, mainly among men given fish oil capsules. One positive trial and one failed replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. give a C.
Why this letter
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on death. DART found 29% lower 2-year mortality in men advised to eat fatty fish after a heart attack (Burr et al., 1989; PMID 2571009).
WHY NOT Bthe replication by the same investigators in men with angina found no reduction in death and higher cardiac death among those advised to eat fish or take fish oil (Burr et al., 2003; PMID 12571649), so the positive result stands unreplicated.
WHAT THIS GRADE DOES NOT COVERfish oil supplements, graded on EBL's omega-3 records, and people without heart disease. It also does not cover women, who were not enrolled, or fish eaten for reasons other than heart disease.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: All-cause and cardiac death (hard)
Last reviewed: November 2026
The trial that would change this grade.
A positive trial of this shape, supported by further trials, would move this entry to B.
Why the current trials fall short
A third trial would settle the conflict between DART and DART-2.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Fish Consumption among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Fish Consumption on ClinicalTrials.gov
Dose, form and timing
None; the trials measured deaths.
Safety
Cautions documented in human studies. Each caution on this record, sorted by what it rests on.
- Higher cardiac death in men with angina advised to eat oily fish or take fish oil, mainly capsules (PMID 12571649)
None recorded.
None recorded.
None recorded.
Does not apply: human harm data are listed above.
Grade history
How this letter has changedLatest: No. 442 · November 2026 · First graded.
New record in the food section. In DART, men told to eat fatty fish after a heart attack had 29% lower 2-year death. When the same group repeated the trial in 3,114 men with angina (DART-2), fish advice did not reduce death and cardiac death was higher, mainly among men given fish oil capsules. One positive trial and one failed replication give a C.PMID 2571009 PMID 12571649
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullTwo papers, each linked to its PubMed record.
Burr et al. (Lancet, 1989; PMID 2571009): DART, randomized factorial trial in 2,033 men who had recovered from a heart attack; advice to eat fatty fish reduced 2-year all-cause mortality by 29%; reinfarction plus heart disease death not significantly affected. Burr et al. (Eur J Clin Nutr, 2003; PMID 12571649): DART-2, randomized factorial trial in 3,114 men under 70 with angina followed 3 to 9 years; all-cause mortality not reduced by fish advice; cardiac death higher (HR 1.26, 95% CI 1.00 to 1.58), mainly among those given fish oil capsules.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
("fish"[tiab] OR "fatty fish"[tiab] OR "oily fish"[tiab]) AND (advice[tiab] OR diet*[tiab]) AND (mortality[tiab] OR reinfarction[tiab]) AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Burr et al., 1989, Lancet (PMID 2571009): PubMed lists no funder for this trial.
- Burr et al., 2003, Eur J Clin Nutr (PMID 12571649): PubMed lists no funder for this trial.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →